Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Dendritic Cell/AML Fusion Cell Vaccine in Treating Patients with Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Trial Status: closed to accrual

This phase I trial studies the side effects of dendritic cell/acute myeloid leukemia (AML) fusion cell vaccine in treating patients with acute myeloid leukemia undergoing donor stem cell transplant. Vaccines made from a person's cancer cells may help the body build an effective immune response to kill cancer cells. Giving dendritic cell/AML fusion cell vaccine may work better in treating patients with acute myeloid leukemia is capable of producing immune responses against leukemia.